SOM3366

SOM3366 is a small molecule drug developed as a selective vesicular monoamine transporter 2 (VMAT2) inhibitor. It is the R-enantiomer of SOM3355, designed to have less effect on the β1-adrenoceptor compared to its parent compound. The drug is being evaluated primarily for the treatment of Tourette syndrome and tardive dyskinesia, both movement and neuropsychiatric disorders. As a VMAT2 inhibitor, it works by modulating synaptic vesicular amine transport, thereby reducing abnormal neurotransmitter release associated with these conditions. SOM3366 represents a new molecular entity in this class and has undergone regulatory guidance from both FDA (pre-IND meeting) and EMA (Scientific Advice). Its development leverages proprietary AI-based technology from its developer.

Other names

R-enantiomer of SOM3355